In focus
Antengene's AnTenGager-D2 Data Selected as TOP150 Abstract at SITC 2026
Antengene presented preclinical results for its AnTenGager-D2 costimulatory T cell engager platform at SITC 2026, where the study was named a TOP150 abstract. The data cover the ATG-109 candidate molecule and its performance in prostate cancer models.
Read the story